Articles from The Ritedose Corporation

COLUMBIA, S.C., Oct. 08, 2026 (GLOBE NEWSWIRE) -- The Ritedose Corporation announced the opening of its new state-of-the-art current Good Manufacturing Practice (cGMP) laboratory, marking a major milestone in the Company's continued growth and reinforcing its position as a pharmaceutical manufacturing and life sciences innovation leader. The new analytical chemistry laboratory, coupled with the expansion of Ritedose's microbiology laboratory at its main manufacturing campus, creates a unique integrated laboratory infrastructure designed to support the Company's continued manufacturing growth while providing comprehensive, in-house analytical services.

Ritedose expands albuterol inhalation solution production and strengthens its role as a trusted source for inhaled solutions

The role will focus on identifying new opportunities and strengthening existing customer relationships to accelerate Ritedose’s continued growth

Employee-led initiative deepens Ritedose's commitment to Midlands nonprofits and the communities they serve

COLUMBIA, S.C., April 23, 2026 (GLOBE NEWSWIRE) -- The Ritedose Corporation (Ritedose), the nation’s leading contract development and manufacturing organization (CDMO) specializing in sterile Blow-Fill-Seal (BFS) production, welcomed 45 international business students from ESCP Business School April 22 as part of an academic exchange that highlighted global leadership and innovation in pharmaceutical manufacturing.

- Generic Tobramycin Inhalation Solution marks the first cystic fibrosis (CF) product in the Company’s portfolio-Antibiotic is primarily used for chronic Pseudomonas aeruginosa infections in patients with CF

COLUMBIA, S.C., Sept. 24, 2025 (GLOBE NEWSWIRE) -- The Ritedose Corporation is investing more than $17 million to further its in-house cGMP laboratory capabilities by expanding its analytical chemistry and microbiology laboratories.